Letrozole
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01006 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | female breast carcinoma | KG + DL |
| 2 | nipple carcinoma | KG + DL |
| 3 | estrogen-receptor negative breast cancer | KG + DL |
| 4 | hormone-resistant breast carcinoma | KG + DL |
| 5 | Ehrlich tumor carcinoma | KG + DL |
| 6 | estrogen-receptor positive breast cancer | KG + DL |
| 7 | bilateral breast carcinoma | KG + DL |
| 8 | breast carcinoma by gene expression profile | KG + DL |
| 9 | breast fibrocystic disease | KG + DL |
| 10 | benign mammary dysplasia | KG + DL |
| 11 | fat necrosis of breast | KG + DL |
| 12 | breast abscess | KG + DL |
| 13 | blunt duct adenosis of breast | KG + DL |
| 14 | apocrine adenosis of breast | KG + DL |
| 15 | lactation disease | KG + DL |
| 16 | breast adenosis | KG + DL |
| 17 | prostate cancer/brain cancer susceptibility | KG + DL |
| 18 | rhabdomyosarcoma (disease) | KG + DL |
| 19 | botryoid-type embryonal rhabdomyosarcoma of the vagina | KG + DL |
| 20 | fibroma of prostate | KG + DL |
| 21 | parameningeal embryonal rhabdomyosarcoma | KG + DL |
| 22 | embryonal extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 23 | benign reproductive system neoplasm | KG + DL |
| 24 | hereditary breast ovarian cancer syndrome | KG + DL |
| 25 | Brenner tumor | KG + DL |
| 26 | prostate leiomyoma | KG + DL |
| 27 | prostate embryonal rhabdomyosarcoma | KG + DL |
| 28 | extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 29 | male reproductive organ cancer | KG + DL |
| 30 | liver sarcoma | KG + DL |
| 31 | benign prostate phyllodes tumor | KG + DL |
| 32 | dermatofibrosarcoma protuberans | KG + DL |
| 33 | ovarian clear cell adenocarcinoma | KG + DL |
| 34 | HIV infectious disease | KG + DL |
| 35 | villoglandular endometrial endometrioid adenocarcinoma | KG + DL |
| 36 | endometrial mixed adenocarcinoma | KG + DL |
| 37 | prostate neoplasm | KG + DL |
| 38 | secretory uterine corpus endometrioid adenocarcinoma | KG + DL |
| 39 | mucin-rich endometrial endometrioid adenocarcinoma | KG + DL |
| 40 | AIDS | KG + DL |
| 41 | endometrial mucinous adenocarcinoma | KG + DL |
| 42 | stage II endometrioid carcinoma | KG + DL |
| 43 | stage I endometrioid carcinoma | KG + DL |
| 44 | prostate cancer | KG + DL |
| 45 | cervical endometrioid adenocarcinoma | KG + DL |
| 46 | ovarian endometrioid adenocarcinoma | KG + DL |
| 47 | rete ovarii adenocarcinoma | KG + DL |
| 48 | rectum mucinous adenocarcinoma | KG + DL |
| 49 | malignant prostate phyllodes tumor | KG + DL |
| 50 | colon mucinous adenocarcinoma | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.